MONROE TOWNSHIP, N.J., Nov. 23, 2018 /PRNewswire/ -- An estimated 400 million medical imaging procedures are performed each year in the United States.1 To demonstrate the company's commitment to the challenges faced by the healthcare professionals involved in those procedures and the patients they serve, Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, reaffirms the company's vision on addressing the diagnostic imaging needs of today and tomorrow.
"As the imaging industry evolves with an emphasis on safe, efficient, cost effective, and personalized patient care, Bracco is at the forefront of that change, constantly advancing our products, services and expertise to offer ever increasing added value to all of our customers today and tomorrow," said Vittorio Puppo, President and CEO of Bracco Diagnostics Inc. "The advances Bracco has made with our product portfolio continuously demonstrate our commitment to address the needs of healthcare providers."
Bracco will highlight its full scope of offerings and advancements with its diagnostic imaging services and solutions portfolio at the 2018 RSNA Annual Meeting (South Hall Level 3, Booth #1911), including Bracco's:
Puppo added, "At Bracco, we take pride in what we do, and our shared vision is evident in every innovation, research opportunity and action we take in our relentless pursuit of better serving our customers, and ultimately to help improve patients' lives."
Visit the Bracco booth (#1911) to learn more.
About Bracco Imaging
Bracco Imaging S.p.A., part of the Bracco Group, is one of the world's leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs.
Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities:
X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers. The diagnostic imaging portfolio is completed by a range of medical devices and advanced administration systems for contrast imaging products.
The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. With on-going research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America, Europe and Japan operating through the Joint Venture Bracco-Eisai Co. Ltd. The Company also operates in Brazil, South Korea, and China through the Joint Venture Bracco Sine Pharmaceutical Corp. Ltd.
Operational investments have been made in order to achieve top quality, compliant and sustainable eco-friendly production. Manufacturing activities are located in Italy, Switzerland, Japan, China, and Germany.
Bracco Imaging is an innovative Research and Development (R&D) structure with an efficient process-oriented approach and a track record of innovation in the diagnostic imaging industry. R&D activities are managed in the three Research Centers located in Italy, Switzerland, and the USA.
To learn more about Bracco Imaging, visit www.braccoimaging.com.
Bracco Diagnostics Inc. Media Relations
1 American Society of Radiological Technologists. State and Federal Licensure Issues. Retrieved from https://www.asrt.org/main/standards-regulations/federal-legislative-affairs/state-and-federal-licensure-issues